New Triple-Drug cocktail shows promise for Tough-to-Treat recurrent cancers
Disease control
Ongoing
This study tests a new combination of three FDA-approved drugs (lenvatinib, pembrolizumab, and paclitaxel) in women whose endometrial, ovarian, fallopian tube, or primary peritoneal cancer has returned after prior treatment. The goal is to see if the triple therapy shrinks tumors…
Phase: PHASE2 • Sponsor: Floor Backes, MD • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC